Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
17 results
  • Lymphoma, Cellular Therapy

18-455          Phase III

A global randomized multicenter phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk transplant-eligible relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (Transform) (View details on

  • Gastric (Stomach) Cancer, Lung Cancer, Head and Neck Cancer, Lymphoma

17-674          Phase I

A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma (View details on

  • Cellular Therapy, Lymphoma

15-404          Phase I

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) (View details on

  • Lymphoma

15-229          Phase I

A Phase 1, Open-Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects with High Risk (IPI 3 Or More) Previously Untreated Diffuse Large B-Cell Lymphoma or Grade 3B Follicular Lymphoma (View details on

  • Lymphoma

17-662          Phase I

A Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL) (View details on

  • Lymphoma, Hodgkin's Disease

19-113          Phase II

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) (View details on

  • Lymphoma, Bone Marrow Transplant

14-566          Phase II

A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma (View details on

  • Lymphoma

19-301          Phase II

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6 (View details on

Showing 1 - 10 of 17 results